GlassScriptPhysician profile
Sajedah Taher
NPI 1548819584
$4,906.64
in general payments reported to CMS, 2019-2025
32 companies · $775 in 2025
The $775 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $908 · 2022: $582 · 2023: $1,642 · 2024: $999 · 2025: $775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,416.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,021.99 | 2021-2025 | |
| Dexcom, INC. | $467.77 | 2023-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Biohaven Pharmaceuticals, INC. | $320.42 | 2021 | |
| Glaxosmithkline, LLC. | $309.52 | 2021-2024 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $239.54 | 2021-2023 | |
| Novo Nordisk INC | $234.99 | 2021-2024 | Ozempic, Rybelsus |
| Boston Scientific Corporation | $219.36 | 2024-2025 | Watchman Flx |
| Amgen INC. | $192.64 | 2021-2023 | Repatha, Otezla, Evenity |
| Sanofi Pasteur INC. | $186.84 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $162.39 | 2021-2022 | |
| Cvrx, INC. | $137.79 | 2025 | Barostim Neo System |
| Pfizer INC. | $127.71 | 2022-2024 | |
| Verrica Pharmaceuticals INC. | $125.00 | 2023 | Ycanth |
| Neurocrine Biosciences, INC. | $124.95 | 2024 | Ingrezza |
| Corcept Therapeutics | $120.43 | 2023-2024 | Korlym |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $115.35 | 2021-2024 | Mounjaro |
| Alkermes, INC. | $114.75 | 2023 | Lybalvi |
| Abiomed | $102.97 | 2023 | Impella |
| Arcutis Biotherapeutics, INC. | $96.88 | 2024 | Zoryve |
| Janssen Pharmaceuticals, INC | $90.15 | 2021 | |
| Sanofi-Aventis U.S. LLC | $85.43 | 2024 | |
| Merck Sharp & Dohme LLC | $63.31 | 2021-2024 | Capvaxive, Gardasil 9, Gardasil |
| Idorsia Pharmaceuticals US INC | $62.40 | 2023 | Quviviq |
| Vanda Pharmaceuticals INC. | $33.57 | 2025 | Fanapt, Hetlioz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.24 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.61 | 2022 | |
| Si-Bone, INC. | $19.61 | 2023 | |
| Eisai INC. | $16.68 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.10 | 2021 | |
| Exact Sciences Corporation | $14.98 | 2023 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $13.50 | 2022 | |
| Vistapharm, INC. | $11.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sajedah Taher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.